This week our sponsors at Life Water Media (Disclosure) hired us to take a closer look at Antibe Therapeutics (TSX: ATE) (OTC: ATBPF), a Canadian biotech company that specializes in anti-inflammation treatments. Why did we pick Antibe to promote? Keep reading to find out!
Company: Antibe Therapeutics
Sector: Biotech (Pharmaceuticals)
Cup and Handle?
The first thing we noticed when looking into Antibe was the distinct cup and handle pattern on the one-year chart. Last June the price jumped to a new high around $6.80 before deflating and finding support around $2.50. Then in February the stock rocketed up before falling again, but more gradually this time, forming the handle. Granted, the stock does not see a whole lot of daily volume. That can make interpreting patterns like this difficult, however, this just looks too distinct to ignore.
Otenaproxesul FDA Approval for Phase III Trials
Antibe’s lead product is Otenaproxesul, a hydrogen sulfide releasing analog to naproxen, a widely used NSAID. What makes Otenaproxesul so exciting is that its phase IIB trials showed it to be effective with significantly less GI side effects. NSAIDs have been known to cause gastrointestinal ulcers and bleeding when used too frequently. If Antibe can provide a safer alternative to NSAIDs when treating inflammatory diseases such as arthritis, they stand to make a lot of money! Last month, the FDA gave the company’s investigational new drug (IND) application clearance. This will enable Antibe to start human clinical trials in the US, something they anticipate initiating later this year in Phase III trials.
With a distinct cup and handle pattern on their one-year chart and soon to be initiated Phase III clinical trials on a potentially game changing arthritis treatment, Antibe Therapeutics is a stock to keep an eye on!
To learn more, check out this link
Through an agreement with a third party, Financial Ineptitude, Inc was paid $110 on 5/08/21 through 5/10/21 to write this promotional content for Antibe Therapeutics (TSX: ATE) (OTC: ATBPF), which contains affiliate links. We are not licensed to give financial advice and nothing in this article should be construed as such. Please do your own research and consult with a financial advisor before making any investment decisions.